CVRX Stock Overview
A commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CVRx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.62 |
| 52 Week High | US$33.14 |
| 52 Week Low | US$6.40 |
| Beta | 1.16 |
| 1 Month Change | -10.98% |
| 3 Month Change | 57.82% |
| 1 Year Change | -58.74% |
| 3 Year Change | 15.13% |
| 5 Year Change | n/a |
| Change since IPO | -51.36% |
Recent News & Updates
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
Dec 26
CVRx: Impressive Top-Line Growth Seems Priced In
Nov 07Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report
Nov 01Recent updates
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
Dec 26CVRx: Impressive Top-Line Growth Seems Priced In
Nov 07Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report
Nov 01Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)
Oct 10Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
Jul 31Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge
Jun 18The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%
May 04Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt
Apr 10The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%
Feb 29Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%
Nov 11Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth
Aug 20CVRx Pursues Revenue Growth But Operating Losses Worsen
Aug 05CVRx: Barostim Story Looks Well Priced In, Overvalued At Just 5x Sales
Jun 21We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth
Apr 12Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33
Feb 18Shareholder Returns
| CVRX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 16.2% | 2.3% | 2.8% |
| 1Y | -58.7% | 10.1% | 24.5% |
Return vs Industry: CVRX underperformed the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: CVRX underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| CVRX volatility | |
|---|---|
| CVRX Average Weekly Movement | 13.7% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CVRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CVRX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 200 | Kevin Hykes | www.cvrx.com |
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally.
CVRx, Inc. Fundamentals Summary
| CVRX fundamental statistics | |
|---|---|
| Market cap | US$313.00m |
| Earnings (TTM) | -US$58.48m |
| Revenue (TTM) | US$47.26m |
7.0x
P/S Ratio-5.7x
P/E RatioIs CVRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVRX income statement (TTM) | |
|---|---|
| Revenue | US$47.26m |
| Cost of Revenue | US$7.48m |
| Gross Profit | US$39.77m |
| Other Expenses | US$98.25m |
| Earnings | -US$58.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.41 |
| Gross Margin | 84.16% |
| Net Profit Margin | -123.75% |
| Debt/Equity Ratio | 75.5% |
How did CVRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 00:21 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CVRx, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |